The double-blind STRIDE trial, conducted at 112 outpatient clinics in North America, Asia and Europe from October 2020 to July 2024, randomized 792 participants (median age 68 years, 25% women, 68% White) with T2D and PAD with intermittent claudication (Fontaine stage IIa) as well as an ankle-brachial index of 0.90 (mean 0.75) or toe-brachial index 0.70 (mean 0.48) to either once-weekly doses of subcutaneous semaglutide (n=396) or placebo (n=396) for 52 weeks
Lower costs for effective GLP-1 medications could diminish employer demand for behavioral programs to treat obesity
Can I take Vitamin B2 and Vitamin C together?
Use an alcohol swab and let the skin dry before injecting
What color is tirzepatide with B12
Patients are advised to eat smaller, more frequent meals, avoid high-fat foods, and stay well hydrated